Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	protein phosphatase 4 complex	PPP4R3B PPP4R3C	4.80e-05	6	38	2	GO:0030289
Domain	Ribosomal_L7Ae	NHP2 RPS12	2.08e-04	11	37	2	PF01248
Domain	Ribosomal_L7Ae/L30e/S12e/Gad45	NHP2 RPS12	2.49e-04	12	37	2	IPR004038
Domain	ZF_TRAF	TRAFD1 FBXO30	2.94e-04	13	37	2	PS50145
Domain	L30e-like	NHP2 RPS12	3.95e-04	15	37	2	IPR029064
Domain	-	NHP2 RPS12	3.95e-04	15	37	2	3.30.1330.30
Domain	SIAH-type	TRAFD1 FBXO30	4.50e-04	16	37	2	IPR013323
Domain	TRAF-like	TRAFD1 FBXO30	1.03e-03	24	37	2	IPR008974
Domain	MYOSIN_MOTOR	MYO5A MYO16	2.57e-03	38	37	2	PS51456
Domain	Myosin_head	MYO5A MYO16	2.57e-03	38	37	2	PF00063
Domain	Myosin_head_motor_dom	MYO5A MYO16	2.57e-03	38	37	2	IPR001609
Domain	CYCLIN	BRF1 CCNP	2.57e-03	38	37	2	SM00385
Domain	MYSc	MYO5A MYO16	2.57e-03	38	37	2	SM00242
Domain	-	BRF1 CCNP	2.84e-03	40	37	2	1.10.472.10
Domain	Cyclin-like	BRF1 CCNP	3.28e-03	43	37	2	IPR013763
Domain	Znf_C2H2	ADAMTS17 BNC1 ZNF526 TRAFD1 ZNF41 KLF5	4.66e-03	805	37	6	IPR007087
Domain	IQ	MYO5A MYO16	1.12e-02	81	37	2	SM00015
Domain	IQ_motif_EF-hand-BS	MYO5A MYO16	1.37e-02	90	37	2	IPR000048
Pubmed	Human Scc4 is required for cohesin binding to chromatin, sister-chromatid cohesion, and mitotic progression.	DSCC1 NIPBL	4.16e-05	9	38	2	16682347
Pubmed	Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling.	COL4A2 KLF5	4.16e-05	9	38	2	12101409
Pubmed	Genomic annotation of 15,809 ESTs identified from pooled early gestation human eyes.	KCTD7 COL4A2 MAPK8IP3	4.35e-05	62	38	3	16368877
Pubmed	A locus for renal malformations including vesico-ureteric reflux on chromosome 13q33-34.	COL4A2 MYO16	1.21e-04	15	38	2	16565260
Pubmed	A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasias.	JAK2 STYK1	1.38e-04	16	38	2	19464057
Pubmed	Expanding the substantial interactome of NEMO using protein microarrays.	JAK2 NHP2 RPS12	2.33e-04	109	38	3	20098747
Pubmed	Cytosolic quality control of mislocalized proteins requires RNF126 recruitment to Bag6.	TRAFD1 TRIM27	2.65e-04	22	38	2	24981174
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	PPP4R3B KDM5B USP9Y NHP2 MYO5A NIPBL MAPK8IP3	4.27e-04	1285	38	7	35914814
Pubmed	K48- and K63-linked ubiquitin chain interactome reveals branch- and length-specific ubiquitin interactors.	N4BP1 DTX2 TRAFD1 TRIM27 FBXO30	4.86e-04	604	38	5	38803224
Pubmed	Ubiquitin-Independent Disassembly by a p97 AAA-ATPase Complex Drives PP1 Holoenzyme Formation.	NHP2 TRIM27 MTUS1 RPS12	6.38e-04	361	38	4	30344098
Pubmed	High-throughput analyses of hnRNP H1 dissects its multi-functional aspect.	KCTD7 DTX2 TRAFD1 GPT2 NHP2 KLF5	7.80e-04	1021	38	6	26760575
Pubmed	The DNA sequence and analysis of human chromosome 13.	COL4A2 FNDC3A INTS6	8.54e-04	170	38	3	15057823
Pubmed	Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?	TRAFD1 BRF1 DOCK6	8.54e-04	170	38	3	23314748
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	KDM5B INTS6 USP9Y DOCK6 NIPBL RPS12	1.05e-03	1082	38	6	38697112
Cytoband	16q12.1	N4BP1 GPT2	3.68e-04	34	38	2	16q12.1
Coexpression	GSE34156_NOD2_LIGAND_VS_TLR1_TLR2_LIGAND_6H_TREATED_MONOCYTE_UP	JAK2 FNDC3A N4BP1 DTX2 TRAFD1 IFIT1B	4.12e-07	200	38	6	M8690
Coexpression	GSE46606_UNSTIM_VS_CD40L_IL2_IL5_3DAY_STIMULATED_IRF4MID_SORTED_BCELL_DN	JAK2 FNDC3A TRAFD1 MYO5A IFIT1B	1.01e-05	200	38	5	M9837
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L3-4_PVALB_HOMER3\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 EPHX2 MTUS1 MYO16	5.14e-07	186	38	5	948815663c212c4311329d503b5991cbbbff9808
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 EPHX2 MTUS1 MYO16	5.56e-07	189	38	5	78cf414b98bcb19deb934409acddaad1cd51b67f
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_2\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	1.47e-05	175	38	4	11f49f00e000cbc137e3540a6d6805cde21d96e6
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_2-Inh_L3-6_PVALB_MFI2_(Chandelier_2)\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	1.57e-05	178	38	4	c982a73955c9c193bcab21d60d453afcc09cd586
ToppCell	facs-Lung-EPCAM-24m-Myeloid-Dendritic_Cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KCTD7 INTS6 GPT2 FBXO30	1.64e-05	180	38	4	5b7d2336ed09d07f6b8dd91c1fa9c5ade633c104
ToppCell	facs-Lung-24m-Hematologic-myeloid-myeloid_dendritic_cell-dendritic_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	KCTD7 INTS6 GPT2 FBXO30	1.64e-05	180	38	4	d33bb00f2b7d07dda9015cb8eafd742c2b2e9ace
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_2\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	1.68e-05	181	38	4	153709b4dd3d81e09f251fa8765b58bed1932fda
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L3-4_PVALB_HOMER3\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 EPHX2 MYO16	1.68e-05	181	38	4	bd7e9437839bca543ca5945df43d6525e6a312a8
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_STON2\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 PPP4R3C MYO16	1.72e-05	182	38	4	08aff7112c9dac0ef5540300516a604782b21169
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	1.75e-05	183	38	4	04d3cc76038b8192c915f1c08c3e26f2ad3b3779
ToppCell	LPS-IL1RA\|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	JAK2 FNDC3A N4BP1 RBBP8	1.79e-05	184	38	4	c066c2ec4f0f1d6eb183fca5c7bb0cd45c9950dc
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	1.79e-05	184	38	4	2ba98708dfd7f1b2a661578a334684094ff453ad
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L3-4_PVALB_HOMER3\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 EPHX2 MTUS1 MYO16	1.95e-05	188	38	4	72cbfe9dc0583dbeafa6cb0945fa370d0c808284
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	1.95e-05	188	38	4	8de5a07301f9b5984680c873e5a92395b5ed3dd3
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	2.03e-05	190	38	4	3f22c118d552345f731d4d49f0bcb5765d93de3b
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 MTUS1 MYO16	2.03e-05	190	38	4	39ab890104b4264c68a968f920f4ccd84f0bc681
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 KLF5 MYO16	2.08e-05	191	38	4	782bc7946417549ffd39e5b596db659436fa01ba
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ADAMTS17 COL4A2 EPHX2 MYO16	2.16e-05	193	38	4	c4b22b62f3cc7bf0ec0eba76e1504c236290bbc9
ToppCell	Neuronal-Inhibitory-iB-iB_2(PVALB)-SCUBE3\|Neuronal / cells hierarchy compared to all cells using T-Statistic	ADAMTS17 COL4A2 MTUS1 MYO16	2.48e-05	200	38	4	2441a36d363b799a4692aa697f969cda056c2d60
ToppCell	Neuronal-Inhibitory-iB-iB_2(PVALB)-SCUBE3-\|Neuronal / cells hierarchy compared to all cells using T-Statistic	ADAMTS17 COL4A2 MTUS1 MYO16	2.48e-05	200	38	4	c7bca638229bd4fd2414171e73fa949e36a10a92
ToppCell	Neuronal-Inhibitory-iB-iB_2(PVALB)-SCUBE3--L2-5\|Neuronal / cells hierarchy compared to all cells using T-Statistic	ADAMTS17 COL4A2 MTUS1 MYO16	2.48e-05	200	38	4	d841dbe2297c3bf62f49bae5921662cd6a47e5c2
ToppCell	tumor_Lung-Endothelial_cells-Tumor_ECs\|Endothelial_cells / Location, Cell class and cell subclass	COL4A2 DOCK6 MTUS1 RPS12	2.48e-05	200	38	4	9c1b30fa96565515a7160f439cadcd51482c41e9
Drug	Iohexol [66108-95-0]; Up 200; 4.8uM; PC3; HT_HG-U133A	EPHX2 BNC1 TRAFD1 DOCK6 MTUS1	1.70e-05	194	38	5	4643_UP
Drug	5213008; Up 200; 18uM; MCF7; HT_HG-U133A_EA	PPP4R3B FNDC3A N4BP1 DOCK6 MTUS1	1.70e-05	194	38	5	898_UP
Drug	Benzocaine [94-09-7]; Down 200; 24.2uM; PC3; HT_HG-U133A	JAK2 BNC1 PPP4R3B FNDC3A MTUS1	1.75e-05	195	38	5	4224_DN
Drug	Sulfisoxazole [127-69-5]; Down 200; 15uM; MCF7; HT_HG-U133A	PPP4R3B FNDC3A DOCK6 KLF5 STYK1	1.88e-05	198	38	5	5622_DN
Drug	(R)-(+)-Atenolol [56715-13-0]; Down 200; 15uM; PC3; HT_HG-U133A	JAK2 PPP4R3B FNDC3A MTUS1 MAPK8IP3	1.88e-05	198	38	5	4259_DN
Drug	estragole oxide	EPHX2 GPT2	4.05e-05	6	38	2	CID000040004
Drug	hartshorn	BNC1 INTS6	9.69e-05	9	38	2	CID000024660
Drug	Suloctidil [54063-56-8]; Up 200; 11.8uM; HL60; HT_HG-U133A	COL4A2 JAK2 N4BP1 MTUS1	1.44e-04	160	38	4	1297_UP
Drug	Thiostrepton [1393-48-2]; Up 200; 2.4uM; HL60; HT_HG-U133A	PPP4R3B BRF1 MTUS1 STYK1	2.46e-04	184	38	4	2462_UP
Drug	H-7 dihydrochloride; Down 200; 100uM; PC3; HT_HG-U133A	KDM5B N4BP1 MTUS1 NIPBL	2.46e-04	184	38	4	5968_DN
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	EPHX2 TRAFD1 KLF5 MAPK8IP3	2.51e-04	185	38	4	6945_UP
Drug	Corticosterone [50-22-6]; Down 200; 11.6uM; MCF7; HT_HG-U133A	JAK2 PPP4R3B RBBP8 MAPK8IP3	2.61e-04	187	38	4	3244_DN
Drug	2-propylpentanoic acid; Down 200; 10000uM; MCF7; HG-U133A	JAK2 N4BP1 NIPBL CCNP	2.67e-04	188	38	4	345_DN
Drug	Cyclosporin A [59865-13-3]; Up 200; 3.4uM; HL60; HT_HG-U133A	COL4A2 JAK2 BRF1 KLF5	2.72e-04	189	38	4	1331_UP
Drug	Rauwolscine hydrochloride [6211-32-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A	JAK2 N4BP1 TRAFD1 NIPBL	2.78e-04	190	38	4	6274_DN
Drug	PHA-00846566E [724718-26-7]; Down 200; 10uM; PC3; HT_HG-U133A	FNDC3A TRAFD1 BRF1 KLF5	2.83e-04	191	38	4	7086_DN
Drug	D dB	INTS6 XPA GPT2	2.88e-04	77	38	3	CID006437867
Drug	Nifedipine [21829-25-4]; Up 200; 11.6uM; PC3; HT_HG-U133A	JAK2 N4BP1 KLF5 STYK1	3.01e-04	194	38	4	1814_UP
Drug	Tolazoline hydrochloride [59-97-2]; Down 200; 20.4uM; PC3; HT_HG-U133A	BNC1 PPP4R3B FNDC3A MTUS1	3.01e-04	194	38	4	4262_DN
Drug	ICI 182,780; Up 200; 0.01uM; MCF7; HT_HG-U133A	TRAFD1 KLF5 MAPK8IP3 STYK1	3.01e-04	194	38	4	6955_UP
Drug	PHA-00745360 [351320-33-7]; Down 200; 10uM; PC3; HT_HG-U133A	N4BP1 BRF1 DOCK6 MAPK8IP3	3.01e-04	194	38	4	4559_DN
Drug	5666823; Down 200; 100uM; MCF7; HG-U133A	N4BP1 TRAFD1 BRF1 DOCK6	3.07e-04	195	38	4	609_DN
Drug	Capsaicin [404-86-4]; Down 200; 13uM; HL60; HT_HG-U133A	JAK2 MTUS1 KLF5 MAPK8IP3	3.07e-04	195	38	4	3034_DN
Drug	Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; PC3; HT_HG-U133A	EPHX2 N4BP1 MTUS1 MAPK8IP3	3.07e-04	195	38	4	4508_DN
Drug	PHA-00767505E [723337-45-9]; Up 200; 10uM; PC3; HT_HG-U133A	JAK2 BNC1 FNDC3A NIPBL	3.07e-04	195	38	4	6545_UP
Drug	Picrotoxinin [17617-45-7]; Down 200; 13.6uM; PC3; HT_HG-U133A	BNC1 PPP4R3B XPA MTUS1	3.07e-04	195	38	4	4260_DN
Drug	Cefsulodin sodium salt [52152-93-9]; Up 200; 7.2uM; MCF7; HT_HG-U133A	BRF1 TRPA1 MAPK8IP3 CCNP	3.07e-04	195	38	4	4148_UP
Drug	STOCK1N-35215; Up 200; 10uM; PC3; HT_HG-U133A	N4BP1 BRF1 CCNP STYK1	3.13e-04	196	38	4	6380_UP
Drug	Triamterene [396-01-0]; Down 200; 15.8uM; HL60; HT_HG-U133A	JAK2 TRAFD1 NIPBL MAPK8IP3	3.13e-04	196	38	4	1861_DN
Drug	Quinic acid [86-68-0]; Down 200; 19.6uM; PC3; HT_HG-U133A	JAK2 N4BP1 XPA BRF1	3.13e-04	196	38	4	7317_DN
Drug	rosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A	JAK2 KLF5 MAPK8IP3 STYK1	3.13e-04	196	38	4	6950_UP
Drug	Betonicine [515-25-3]; Up 200; 25.2uM; HL60; HT_HG-U133A	BNC1 DOCK6 MTUS1 KLF5	3.13e-04	196	38	4	2207_UP
Drug	novobiocin sodium, USP; Down 200; 100uM; ssMCF7; HG-U133A	N4BP1 TRAFD1 BRF1 CCNP	3.13e-04	196	38	4	499_DN
Drug	estradiol, USP; Down 200; 0.01uM; ssMCF7; HG-U133A	COL4A2 TRAFD1 BRF1 CCNP	3.13e-04	196	38	4	373_DN
Drug	Ofloxacin [82419-36-1]; Down 200; 11uM; PC3; HT_HG-U133A	COL4A2 EPHX2 FNDC3A DOCK6	3.13e-04	196	38	4	3673_DN
Drug	Diphemanil methylsulfate [62-97-5]; Down 200; 10.2uM; MCF7; HT_HG-U133A	FNDC3A TRAFD1 NIPBL STYK1	3.13e-04	196	38	4	1494_DN
Drug	Loxapine succinate [27833-64-3]; Down 200; 9uM; MCF7; HT_HG-U133A	N4BP1 DOCK6 MAPK8IP3 STYK1	3.13e-04	196	38	4	1516_DN
Drug	Rauwolscine hydrochloride [6211-32-1]; Up 200; 10.2uM; MCF7; HT_HG-U133A	JAK2 BRF1 DOCK6 MAPK8IP3	3.13e-04	196	38	4	2778_UP
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	EPHX2 TRAFD1 DOCK6 MAPK8IP3	3.19e-04	197	38	4	1467_UP
Drug	Midecamycin [35457-80-8]; Down 200; 5uM; MCF7; HT_HG-U133A	N4BP1 BRF1 DOCK6 MAPK8IP3	3.19e-04	197	38	4	1526_DN
Drug	Thioproperazine dimesylate [2347-80-0]; Down 200; 6.2uM; PC3; HT_HG-U133A	EPHX2 KDM5B BRF1 NIPBL	3.19e-04	197	38	4	2073_DN
Drug	Glycopyrrolate [596-51-0]; Down 200; 10uM; MCF7; HT_HG-U133A	PPP4R3B TRAFD1 MAPK8IP3 STYK1	3.19e-04	197	38	4	4709_DN
Drug	Cefoxitin sodium salt [33564-30-6]; Up 200; 8.8uM; PC3; HT_HG-U133A	FNDC3A N4BP1 BRF1 DOCK6	3.19e-04	197	38	4	7148_UP
Drug	STOCK1N-35696; Down 200; 15uM; MCF7; HT_HG-U133A	JAK2 N4BP1 DOCK6 KLF5	3.19e-04	197	38	4	6577_DN
Drug	Amidopyrine [58-15-1]; Up 200; 17.2uM; PC3; HT_HG-U133A	KDM5B N4BP1 MTUS1 NIPBL	3.25e-04	198	38	4	2060_UP
Drug	Cephalexin monohydrate [23325-78-2]; Down 200; 11uM; PC3; HT_HG-U133A	N4BP1 TRAFD1 NIPBL MAPK8IP3	3.25e-04	198	38	4	4654_DN
Drug	Cephalothin sodium salt [58-71-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A	FNDC3A BRF1 DOCK6 MAPK8IP3	3.25e-04	198	38	4	6819_UP
Drug	Merbromin [129-16-8]; Up 200; 5uM; MCF7; HT_HG-U133A	TRAFD1 DOCK6 KLF5 STYK1	3.25e-04	198	38	4	3439_UP
Drug	Procaine hydrochloride [51-05-8]; Down 200; 14.6uM; PC3; HT_HG-U133A	COL4A2 JAK2 MAPK8IP3 STYK1	3.25e-04	198	38	4	6329_DN
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HG-U133A	N4BP1 NIPBL MAPK8IP3 CCNP	3.31e-04	199	38	4	1907_DN
Drug	Eserine sulfate, physostigmine sulfate [64-47-1]; Down 200; 6.2uM; HL60; HG-U133A	N4BP1 DSCC1 NIPBL MAPK8IP3	3.31e-04	199	38	4	1776_DN
Drug	Dacarbazine [4342-03-4]; Up 200; 22uM; MCF7; HT_HG-U133A	EPHX2 FNDC3A DOCK6 STYK1	3.31e-04	199	38	4	6816_UP
Drug	dexamethasone; Down 200; 1uM; MCF7; HG-U133A	DSCC1 MTUS1 NIPBL CCNP	3.31e-04	199	38	4	123_DN
Drug	Bephenium hydroxynaphthoate [3818-50-6]; Down 200; 9uM; PC3; HT_HG-U133A	JAK2 PPP4R3B N4BP1 MAPK8IP3	3.31e-04	199	38	4	4668_DN
Drug	Propranolol hydrochloride [318-98-9]; Down 200; 13.6uM; HL60; HT_HG-U133A	PPP4R3B DOCK6 MTUS1 MAPK8IP3	3.31e-04	199	38	4	3059_DN
Drug	tetraethylenepentamine pentahydrochloride; Up 200; 100uM; HL60; HG-U133A	N4BP1 DSCC1 DOCK6 NIPBL	3.31e-04	199	38	4	412_UP
Drug	Meclocycline sulfosalicylate [73816-42-9]; Up 200; 5.8uM; MCF7; HT_HG-U133A	EPHX2 TRAFD1 BRF1 DOCK6	3.31e-04	199	38	4	4982_UP
Drug	Procainamide hydrochloride [614-39-1]; Down 200; 14.8uM; MCF7; HT_HG-U133A	JAK2 DOCK6 MTUS1 NIPBL	3.31e-04	199	38	4	2618_DN
Drug	Acenocoumarol [152-72-7]; Up 200; 11.4uM; PC3; HT_HG-U133A	COL4A2 PPP4R3B TRAFD1 MTUS1	3.38e-04	200	38	4	2077_UP
Drug	ICI 182,780; Down 200; 0.01uM; MCF7; HG-U133A	BNC1 TRPA1 MTUS1 CCNP	3.38e-04	200	38	4	310_DN
Drug	Haloperidol [52-86-8]; Down 200; 10.6uM; PC3; HG-U133A	DSCC1 NIPBL MAPK8IP3 CCNP	3.38e-04	200	38	4	1955_DN
Drug	Gabapentin [60142-96-3]; Down 200; 23.4uM; MCF7; HT_HG-U133A	PPP4R3B N4BP1 BRF1 MAPK8IP3	3.38e-04	200	38	4	7229_DN
Disease	susceptibility to common cold measurement	FNDC3A MYO5A MYO16	4.31e-05	54	37	3	EFO_0008417
Disease	liver cancer (is_marker_for)	JAK2 GPT2	5.48e-05	9	37	2	DOID:3571 (is_marker_for)
Disease	Intellectual Disability	ZNF526 XPA BRF1 GPT2 MAPK8IP3	2.28e-04	447	37	5	C3714756
Disease	HDL cholesterol change measurement	FNDC3A DOCK6	4.15e-04	24	37	2	EFO_0007805

Protein segments in the cluster

Peptide	Gene	Start	Entry
YCMKLLEETGICVVP	GPT2	466	Q8TD30
TCMERGYIKEDLDPC	RBBP8	861	Q99708
PGEDEYPICVLMEKA	BNC1	901	Q01954
MPVAEDEIKPYISRC	COL4A2	1576	P08572
ACKMEECVLPEPAFL	CCNP	161	Q9H8S5
VVVDDKPCELYCSPL	ADAMTS17	626	Q8TE56
CTDCEPMVIDKLPFD	INTS6	311	Q9UL03
PDGCPDEIYMIMTEC	JAK2	1091	O60674
CVFKEEMPITPYECP	KCTD7	191	Q96MP8
CYDEEVVKELMPLVV	MAPK8IP3	46	Q9UPT6
VSYCLIDDECPLMVP	MTUS1	341	Q9ULD2
DPGESVYEEMKCCLP	MYO16	1426	Q9Y6X6
VPPDEDCIICMEKLS	DTX2	406	Q86UW9
DVMDVIAICCPKYKD	NIPBL	2706	Q6KC79
SPEMAEKEDYICVRC	KDM5B	1521	Q9UGL1
DECIMDVVGCLEYDP	PPP4R3B	216	Q5MIZ7
DECIMDVVGCLEYDP	PPP4R3C	216	Q6ZMV5
APPEIEEYCMEVLCK	EPHX2	301	P34913
LEPEEMIEHCLKCYG	DSCC1	236	Q9BVC3
ISECCEPYMVLKEVD	DOCK6	351	Q96HP0
CYSVEMSPIEKDEPR	FNDC3A	696	Q9Y2H6
PSRYRMECPEVDCEE	IFIT1B	131	Q5T764
VVEKREEAIPLPCMC	FBXO30	711	Q8TB52
FTHCPDVCPEELEKM	SCO1	166	O75880
LPIEVYCHLPVMCED	NHP2	86	Q9NX24
EPLKLYCEEDQMPIC	TRIM27	101	P14373
ADEIMLPCEFCEELY	TRAFD1	286	O14545
EGCCTEKLPLYMVLE	STYK1	181	Q6J9G0
CPITEMIEYLPECMK	TRPA1	621	O75762
CDEPMYVKLVEALCA	RPS12	56	P25398
MTLAKACELCPEEEP	USP9Y	2466	O00507
MKIDLEEECDPPSYT	BRF1	281	Q92994
PVMEFDYVICEECGK	XPA	96	P23025
IHPEEKLYVCTECVM	ZNF41	306	P51814
EVKMEPYECPECSTL	ZNF526	191	Q8TF50
PPEDLVQTRCEMEKY	KLF5	81	Q13887
PLCIFCELMGVDYEE	MYO5A	356	Q9Y4I1
ELEERECYPKDMHCI	N4BP1	76	O75113